AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials

Published on 11 Nov 2024 on Bloomberg · via Yahoo Finance

(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trials...

Read the rest of the article

Start tracking your investments with Statfolio

AbbVie Inc. (NYSE:ABBV) will increase its dividend from last year's comparable payment on the 14t...

Simply Wall St. · via Yahoo Finance 17 Nov 2024

AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final stag...

Insider Monkey · via Yahoo Finance 16 Nov 2024

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of...

247wallst.com 16 Nov 2024

(Bloomberg) -- Health stocks slumped on Friday as Wall Street weighed the impact that prominent...

Bloomberg · via Yahoo Finance 15 Nov 2024

Key Position Reductions Conversely, reductions were made in several holdings: AbbVie Inc (NYSE:AB...

GuruFocus.com · via Yahoo Finance 14 Nov 2024

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a...

Benzinga · via AOL 12 Nov 2024

As of 2024-11-12, AbbVie Inc's intrinsic value as calculated by the Discounted Earnings model is...

GuruFocus.com · via Yahoo Finance 12 Nov 2024

On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-dai...

Benzinga 11 Nov 2024

(Bloomberg) -- AbbVie Inc. shares fell the most in more than four years after two mid-stage trial...

Bloomberg · via Yahoo Finance 11 Nov 2024

AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage tri...

Invezz 11 Nov 2024